Breaking News, Collaborations & Alliances

Roche, Inovio in Immunotherapy Development Pact

To collaborate on therapies targeting prostate cancer and hepatitis B

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche and Inovio Pharmaceuticals have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio’s multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The compounds, currently in preclinical development, have generated promising T-cell responses in animal models.   Roche acquired an exclusive license for Inovio’s DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B), as well as th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters